Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMG 193 (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Gastrointestinal cancer; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions
Sponsors Amgen

18 Dec 2024 Planned End Date changed from 30 Apr 2028 to 25 Feb 2029.
18 Dec 2024 Planned primary completion date changed from 1 May 2026 to 26 Feb 2027.
03 Oct 2024 Planned End Date changed from 28 Nov 2027 to 30 Apr 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com